
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG in a new bladder cancer setting, supported by cohort B of the phase 2/3 QUILT-3.032 trial (NCT03022825). Which population does this expanded indication cover?





